ESA and iron therapy in chronic kidney disease: A balance between patient safety and hemoglobin target

Kidney International

Volumn 86, Issue 4, 2014, Pages 676-678

  Hung, Szu Chun ^a   Tarng, Der Cherng ^b,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; IRON COMPLEX; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN; IRON;

ANEMIA; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE SEVERITY; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFLAMMATION; IRON DEFICIENCY; IRON DEPLETION; IRON THERAPY; JAPAN; MORTALITY; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; REVIEW; THROMBOCYTOSIS; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; BLOOD; CHRONIC KIDNEY FAILURE; FEMALE; MALE; METABOLISM; RENAL REPLACEMENT THERAPY;

FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926019284     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.179     Document Type: Note

References (15)

1. Freburger JK, Ng LJ, Bradbury BD et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012; 125: 906-914.
2. Kuragano T, Matsumura O, Matsuda A et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/ mortality in maintenance hemodialysis patients. Kidney Int 2014; 86: 845-854.
3. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
4. Besarab A. What are common misconceptions in dialysis patient care? Anemia and iron management. Semin Dial 2011; 24: 498-503.
5. Solomon SD, Uno H, Lewis EF et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
6. Drüeke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217.
7. Tarng DC. The conundrum of serum ferritin measurement in patients with chronic kidney disease. Nat Clin Pract Nephrol 2009; 5: 66-67.
8. Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol Suppl 2006; 1: S9-S18.
9. Hung SC, Tarng DC. Bone marrow iron in CKD: correlation with functional iron deficiency. Am J Kidney Dis 2010; 55: 617-621.
10. Ford BA, Coyne DW, Eby CS et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009; 75: 104-110.
11. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. KDIGO Anemia Work Group. Kidney Int Suppl 2012; 2: 1-335.
12. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736.
13. Hasegawa T, Bragg-Gresham JL, Pisoni RL et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 2011; 79: 340-346.
14. Macdougall IC, Bock A, Carrera F et al. The FIND-CKD study-a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014; 29: 843-850.
15. Hung SC, Lin YP, Tarng DC. Erythropoiesisstimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc 2014; 113: 3-10.